# Drivers of disengagement from care during the first six months on antiretroviral therapy for HIV in South Africa: a mixed-methods study

Mhairi Maskew<sup>1§</sup>, Nyasha Mutanda<sup>1</sup>, Nancy Scott<sup>2</sup>, Allison Morgan<sup>2</sup>, Mariet Benade<sup>1,2,3</sup>, Vinolia Ntjikelane<sup>1</sup>, Linda Sande<sup>1</sup>, Lufuno Malala<sup>4</sup>, Musa Manganye<sup>4</sup>, Sydney Rosen<sup>1,2</sup>

#### Institutional affiliations:

<sup>1</sup>Health Economics and Epidemiology Research Office, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

<sup>2</sup>Department of Global Health, Boston University School of Public Health, Boston, MA, USA <sup>3</sup>Department of Medical Microbiology, Amsterdam University Medical Center, Amsterdam, The Netherlands

<sup>4</sup>HIV/AIDS Treatment, Care and Support, South African National Department of Health, Pretoria, South Africa

#### <sup>§</sup>Corresponding author: Mhairi Maskew

Health Economics and Epidemiology Research Office, 32 Princess of Wales Terrace, Parktown, Johannesburg, 2193, South Africa. Tel +27 010 001 7930

Email: mmaskew@heroza.org.

#### Email addresses of authors:

Author	E-mail	ORCID ID
Mhairi Maskew	<u>mmaskew@heroza.org</u>	0000-0003-4238-0200
Nyasha Mutanda	<u>nmutanda@heroza.org</u>	0000-0002-2464-5124
Nancy Scott	<u>nscott@bu.edu</u>	0000-0002-4713-4642
Allison Morgan	juntunen@bu.edu	0000-0001-8877-5107
Mariet Benade	mbenade@bu.edu	0000-0001-9498-3199
Vinolia Ntjikelane	vntjikelane@heroza.org	0009-0003-2805-6890
Linda Sande	<u>lsande@heroza.org</u>	0009-0003-4230-5961
Lufuno Malala	lufuno.malala@health.gov.za	0009-0001-7695-3671
Musa Manganye	<u>Musa.Manganye@health.gov.za</u>	0000-0001-8420-0613
Sydney Rosen	<u>sbrosen@bu.edu</u>	0000-0002-6560-2964

#### Keywords:

HIV, South Africa, antiretroviral therapy, retention, cohort study, mixed-methods

# Word count:

Abstract: 342/350 Main text: 5701/5000 (includes Table 5 in word count)

#### 1 Abstract

Introduction: For clients on HIV treatment in sub-Saharan Africa, disengagement from HIV care in the
early treatment period is a critical obstacle to achieving UNAIDS's second 95 target. While South Africa's
Differentiated Service Delivery Guideline on Fast Track Initiation and Counseling (FTIC) define normative
procedures, the effect of guideline implementation and the underlying drivers of disengagement remain
unclear.

7

8 Methods: The PREFER mixed-methods study enrolled a prospective cohort of adult clients initiating ART, 9 returning to care after a period of disengagement or already on ART for ≤6 months at 18 public sector 10 healthcare facilities in South Africa. A survey collected data on demographic and clinical characteristics 11 and preferences of participants who were followed up through routinely-collected medical visit records 12 for up to 7 months after treatment initiation to estimate continuity of HIV care (attended all scheduled 13 visits within 28 days). Focus group discussions (FGDs) were conducted approximately 12 months after 14 enrollment among a subset of participants who had expressed concerns about treatment retention. 15

16 **Results**: During the study period 7/9/2022-30/6/2023, PREFER-SA enrolled 1,049 participants (72%) 17 female, median age=33 years, 24% with CD4 count<200cells/mm<sup>3</sup>); 122 of whom also participated in 18 focus group discussions. By 6 months on ART, 23% were not continuously in HIV care. Those newly 19 initiating ART at study enrollment were more likely to have disengaged or interrupted treatment by 6 20 months as those who had remained in care for ≥1 visit. Disengagement was also more likely among men 21 and younger (18-24 years) participants, those reporting food scarcity, and those initiated on regimens 22 other than Dolutegravir. Disengagement did not differ by gender, relationship status, or CD4 count. 23 Qualitative FGD results suggest participants experience barriers to adherence within and between all 24 levels of the socio-ecologic model. Challenges related to the facility experience were most prominent. 25 26 Conclusions: Among adults initiating or re-initiating ART in South Africa, the highest risk of

disengagement is immediately after initiation. We identified several potentially modifiable individual and
social characteristics associated with early disengagement. Improving the patient facility experience and
strengthening implementation of SA's Service Delivery Guidelines may increase retention during the
early treatment period.

31

32 Word count: 342 words

# 33 Introduction

34

35 The successful implementation of universal access to antiretroviral therapy (ART) for HIV treatment has 36 achieved global targets for reaching clients living with HIV in many African countries with high burdens of 37 HIV. Despite these successes, optimal outcomes for HIV treatment have not yet been achieved, due to 38 losses from care after ART initiation. The first six months after ART initiation, dubbed the "early 39 retention" period[1], remain the period of highest risk for interruption or disengagement[2]. In a recent 40 study in South Africa that relied on routinely collected electronic medical record (EMR) data, 16% of ART 41 initiators had disengaged by 6 months. Another 14% had experienced an interruption of more than 28 42 days during that period, before returning to care, and an interruption in the early treatment period was a 43 strong predictor of disengagement between 7 and 12 months, with a relative risk of disengagement of 44 1.76 compared to those who had not interrupted[3]. 45

46 In addition to the challenges associated with starting any new kind of chronic medical care, achieving 47 retention in care during the early treatment period requires overcoming some specific barriers. Clients 48 presenting for ART initiation fall generally into three categories. The first category comprises the quarter 49 to a third of clients who continue to present for treatment initiation with very low CD4 counts[4,5] or in 50 WHO stage III or IV requiring additional clinical care for advanced HIV disease (AHD) [6]. The second 51 category is for the high proportion of patients who have prior ART experience and are re-initiating ART 52 after previously disengaging from care. Recent studies indicate that half or more of those who present 53 for "initiation" in South Africa have prior ART experience[7,8]. Individuals who know their status and 54 have already started and stopped ART at least once (re-initiators) may face the same barriers to 55 retention again, if they have not received intervention related to those barriers. Re-initiators often 56 present with AHD as well. Finally, the third category includes naive initiators with higher CD4 counts and 57 in WHO stage I or II. Starting CD4 counts have climbed steadily since the introduction of universal 58 treatment in 2016 for those who do not have AHD[9]. In the contemporary era these clients, who are the 59 prototypical patient for whom guidelines were originally designed, likely comprise only a third or fewer 60 of those presenting for treatment initiation.

61

Because of their high risk of disengagement, more attention is needed to all three of the categories of
early treatment clients. Neither of the major treatment cascade-related service delivery innovations of
the past decade--same-day initiation of ART [10] and differentiated models of HIV care for clients

65 established and stable on ART [11]--address the early treatment period. Research on retention in HIV 66 care, moreover, has generally focused on long-term attrition from care, regarding the first six months as 67 a uniform period that marks the shortest interval before a measurable outcome (retention or viral 68 suppression) can be assessed [12]. Research is needed to identify and understand potential drivers of 69 disengagement during the early treatment period so that client-appropriate interventions can be 70 developed. Here, employing a mixed-methods approach to characterize the early treatment period in 71 South Africa, we identify associations between client characteristics and early treatment outcomes in the 72 PREFER study and explore client perceptions of barriers to adherence in their first six months on 73 treatment.

74

# 75 Methods

76

# 77 Study design

78 PREFER was an observational, prospective cohort study conducted in South Africa (7 September 2022 -79 30 June 2023) that aimed to describe and understand the needs of clients both newly initiating and re-80 initiating ART in order to inform the design of DSD models for the early HIV treatment period and 81 improve early treatment outcomes [13]. During the study period, clients presenting for ART initiation or 82 re-initiation or on ART for less than 6 months (i.e. within 6 months of initiation) were enrolled during a 83 routine HIV care clinic visit and administered a baseline survey with quantitative and open-ended 84 questions. Follow up included passive medical record review and participation by a subsample of survey 85 responders in focus group discussions (FGDs).

86

# 87 Study sites and population

88 PREFER was conducted at 18 healthcare facilities in South Africa that had large ART client volumes and 89 utilized the national electronic medical record system for HIV (TIER.Net). The study sequentially enrolled 90 clients that were  $\geq$ 18 years old, initiating, re-initiating, or on ART for  $\leq$ 6 months and were able to provide 91 written informed consent. Consent included participation in the baseline survey, permission to access 92 medical records, and agreement to be contacted for follow-up within 12 months if more information was 93 sought. During screening, clients who were unwilling to take the time required to complete the survey 94 on the day of consent, unable to communicate in one of the languages into which the survey was 95 translated, or judged by clinic or study staff to be physically or emotionally unable to provide consent or 96 participate in all study procedures were excluded.

9	7

97	
98	During the period of PREFER enrollment, the 2019/2020 South African ART guidelines were in place.
99	They recommended a standard first-line ARV regimen of tenofovir, emtricitabine and dolutegravir
100	[14,15]. Standard of care for the first six months on ART South Africa included 5-7 facility visits for clinical
101	consultation, laboratory tests, and medication dispensing, with the first routine viral load (VL) test
102	conducted at 6 months post initiation. Eligibility for less intensive models of care (sometimes known as
103	differentiated models) required at least 6 months' experience on ART and documentation of a
104	suppressed viral load, making early treatment clients ineligible for South Africa's repeat prescription
105	strategies[14,15]. (We note that new guidelines were issued in 2023 and have revised the schedule for
106	the early treatment period and eligibility criteria for less intensive models of care[16]; these are
107	discussed further below.)
108	
109	Data sources, recruitment, and enrollment
110	
111	The PREFER survey instrument was an interviewer-administered structured questionnaire that collected
112	self-reported data on a client's demographic characteristics and socio-economic status, HIV testing
113	history, HIV treatment history, current HIV care and treatment experience, other healthcare, preferences
114	for treatment delivery, expectations, and costs of seeking care[13]. Participants were then passively
115	followed up through EMR data from TIER.Net and South Africa's National Health Laboratory Services
116	database and from paper records and registers maintained at the study sites.
117	
118	At the study sites, clinic staff informed potentially eligible clients that they may be eligible to participate
119	in a research study when the patient checked in at the reception desk. Clients were recruited
120	consecutively as they arrived at each facility, based on availability of study interviewers.
121	
122	Roughly one year after the baseline survey, a subset of those who consented to follow-up were invited to
123	participate in a qualitative FGD to explore participant experience in the early treatment period.
124	Approximately 15 FGDs, each with 8-12 participants, were conducted in selected PREFER study facilities
125	chosen to capture both urban and rural populations. We aimed for a maximum of 180 participants, a
126	sample size that was expected to reach saturation in interview themes, after which no new insights
127	would reasonably be expected to emerge. FGD participants were purposively invited based on responses
128	to the PREFER quantitative survey that indicated they anticipated experiencing, or had already

129	experienced, challenges to adherence in the first six months. These included having missed a scheduled
130	clinic visit by 2-3 days in the past, anticipating difficulty in taking daily medication or picking up
131	medications, or reporting that the care that they received in the clinic was worse than they had
132	expected. FGD guides were designed to elicit perspectives on the challenges faced by clients and factors
133	that enabled adherence in the early treatment period[13]. Focus groups were conducted by two study
134	research assistants, one of whom served as the moderator.
135	
136	Outcomes and statistical analysis
137	
138	The primary outcome for this analysis was retention in HIV care by 6 months after ART initiation. We
139	classified retention into three patterns of engagement derived from observed visit attendance at
140	scheduled clinical or medication pickup visits during the first 6 months after initiation: (i) continuously in
141	care if all scheduled visits during the first 6 months after initiation were observed within 28 days of
142	scheduled visit date or the client record indicated a documented transfer to another care facility prior to
143	the 6-month outcome date; (ii) <i>not continuously in care-disengaged</i> if no visits were observed in the
144	EMR after ART initiation, or at least one additional visit post initiation was observed but the last
145	scheduled visit was not attended and no further visits were observed in the EMR, or a known date of
146	death was documented in the EMR; or (iii) not continuously engaged in carecyclical if at least one visit
147	post initiation was attended >28 days after the scheduled visit date (Table 1).
<b>T</b> 41	post initiation was attended >20 days after the scheduled visit date (Table 1).

148

# 149 Table 1: Retention in care outcome definitions

150

Pattern	Sub-pattern	Definitions
Continuously in care	In care	All scheduled visits during the first 6 months after initiation observed within 28 days of scheduled visit date
	Transferred	Documented transfer to another care facility prior to 6- month date
Not continuously in care	Died	Documented date of death in EMR prior to 6-month date
	Immediately disengaged	No visit after the ART initiation visit observed in the EMR
disengaged	Disengaged from care during first 6 months on ART	≥1 visit after ART initiation visit observed in the EMR; last scheduled visit in 6-month period not attended
Not continuously in carecyclical	Treatment interruption followed by re-engagement in care by 6 months on ART	≥1 visit after ART initiation visit attended >28 days late during the first 6 months on ART

151

152 Our secondary outcome was HIV viral load (VL) suppression by 6 months on ART. To account for newly

updated South African guidelines recommending VL testing as early as 3 months after ART initiation,

154 which came into effect during our enrollment period [16], we included any VL test result observed in 155 months 3-7 after initiation. We then classified each viral load result observed into one of three 156 suppression categories: 1) VL suppressed (VL test result <50 copies/mL); 2) low grade viraemia (VL test 157 result 50-1000 copies/mL; or 3) VL unsuppressed (VL test result >1000 copies/mL). 158 159 We first describe characteristics and crude outcomes of enrolled participants using frequencies and 160 simple proportions for categorical variables and medians with interquartile ranges for continuous 161 variables. We then report the crude analysis showing simple proportions with 95% confidence intervals 162 of patients not continuously in care at 6 months on ART and VL suppression results. Next, we present a 163 simple unadjusted comparison of outcome groups (continuously or not continuously in care at 6 months) 164 with respect to baseline predictors of outcomes. Potential predictors included demographic and clinical 165 variables, preferences and experiences reported in the PREFER survey as well as geographic and facility-166 level factors (urban vs rural setting, facility type). Finally, we use a log-linear regression model to 167 estimate crude risk ratios and their corresponding 95% confidence intervals and utilize the change-in-168 estimate approach to estimate an adjusted model.

169

# 170 Qualitative analysis

171

For qualitative data analysis, we used a combination inductive-deductive approach to develop a
codebook to align the FGD guide, the quantitative survey, and the published literature. Two coders
coded an initial set of transcripts and compared coding to ensure consistency. Discrepancies were
resolved together, and one coder completed coding the remaining transcripts.

176

177 We conducted a content analysis and situated the emergent themes within the Socio-Ecological Model 178 (SEM) framework to understand barriers and facilitators within and between levels The SEM positions 179 individuals within layers of influence [17], such as individual (e.g. one's age, income, health history, etc.); 180 interpersonal (e.g. family relationships and interactions, social support); community (e.g. social 181 networks, community sentiments, belonging, built environment); and societal (e.g. policy, social norms, 182 economic opportunity, etc.). Such influences interact with each other in positive and negative ways and 183 together shape peoples' lived experiences. The model has been used by researchers and stakeholders to 184 understand contributors to poor health and identify opportunity for health delivery and promotion[18]. 185 We adapted the SEM for our population to identify barriers at the individual, interpersonal, health

- 186 facility, and community levels to understand how facility operations and community sentiments affect
- 187 clients' care-seeking behaviors. Emergent FGD themes are presented with accompanying illustrative
- 188 quotes and triangulated with quantitative findings within the results and discussion.
- 189
- 190 Ethics review
- 191
- 192 The PREFER study was approved by the Boston University Institutional Review Board (South Africa H-
- 193 42726, May 20, 2022) and by the University of the Witwatersrand Human Research Ethics Committee
- 194 (South Africa M220440, August 23, 2022). The protocol for South Africa was approved by Provincial
- 195 Health Research Committees through the National Health Research Database for each study district
- 196 (August 1, 2022 for West Rand; September 1, 2022 for King Cetshwayo and August 28, 2022 for
- 197 Ehlanzeni). The study is registered with ClinicalTrials.gov (NCT05454839).
- 198
- 199 Results
- 200

# 201 Characteristics of enrolled study participants


202

203 During the study enrollment period (7 September 2022 - 30 June 2023), we screened a total of 1,115 204 potential participants and enrolled 1,098 (Figure 1). Clients who refused consent (n=1) or had enrolled 205 previously (n=11) were excluded, as were those who had been on ART for >6 months at screening date. 206 An additional 2 clients were enrolled but their survey data were not completed and they were excluded 207 from further analysis. A total of 1.049 participant records were successfully linked to the EMR and 208 included in the final analytic sample to ascertain 6-month retention outcomes. We identified 481 clients 209 eligible to participate in focus group discussions, of whom 155 were contacted; 122 were enrolled in 15 210 FGDs and 32 declined. Reasons for not participating included working and not available during the week 211 (n=10); relocation (n=9); unable to confirm a date available (n=5); not interested (n=3); medical reasons 212 (n=2); and failure to arrive despite accepting (n=3).

213

214 Figure 1: PREFER study enrolment flow chart

215



216

217 218 Table 2 presents the demographic and socioeconomic characteristics of 1,049 enrolled participants 219 included in the 6-month outcomes analysis. The final linked sample did not differ substantively from the 220 analytic sample with respect to baseline covariates. A majority of participants were female (72%); the 221 median age was 33 years (IQR 27-40 years). More than half of participants were unemployed and 222 reported that access to money for healthcare would be difficult. Over 40% were initiating or reinitiating 223 ART on the day of study enrolment, and a guarter had presented for ART initiation with a CD4 count 224 <200cells/mm<sup>3</sup>. FGD participants were primarily female (84%) and had generally similar demographic 225 characteristics to the full analytic sample, despite being deliberately selected because they had 226 anticipated or experienced barriers to adherence. 227 228 Table 2: Demographic and socio-economic characteristics of enrolled participants 229

Characteristic	Final linked sample (n=1,049)	Qualitative FGD sample (n=123)	
Age (median, IQR)	33 (27, 40)	33 (28, 41)	
Gender (n, % female)	750 (71%)	101 (83%)	
Marital status			
Live with primary partner	334 (32%)	34 (28%)	
Do not live with a partner	488 (47%)	59 (48%)	
Do not have a partner/spouse	227 (22%)	29 (24%)	
Education level			
Primary or less	395 (38%)	38 (31%)	
Secondary	501 (48%)	66 (54%)	
Post-secondary	153 (15%)	18 (15%)	
Employment status			
Formal employment	228 (22%)	15 (12%)	
Informal employment	206 (20%)	24 (20%)	
Unemployed	538 (51%)	73 (60%)	
Student/trainee	77 (7%)	10 (8%)	
Food scarcity			
Never/seldom	805 (77%)	90 (74%)	
Sometimes/often	244 (23%)	32 (26%)	
Access to R100 (\$6) for healthcare if needed	244 (2000)	32 (2070)	
Easy	23 (47%)	45 (37%)	
Difficult	26 (53%)	77 (63%)	
District	20 (3370)	,, (05/0)	
West Rand	349 (33%)	40 (33%)	
Ehlanzeni	350 (33%)	32 (26%)	
King Cetshwayo	350 (33%)	50 (41%)	
Urban/rural facility	550 (5576)	50 (41%)	
Rural	481 (46%)	50 (41%)	
Urban	568 (54%)	72 (59%)	
	508 (54%)	72 (3978)	
ART status at study enrolment Self-reported newly initiating	296 (28%)	35 (29%)	
Self-reported re-engaging	157 (15%)	21 (17%)	
On treatment	596 (57%)	66 (54%)	
WHO staging at initiation	004 (86%)		
Stage 1	904 (86%) 82 (8%)	96 (79%) 11 (0%)	
Stage 2	82 (8%)	11 (9%)	
Stages 3 and 4	41 (4%)	4 (3%)	
Unknown Brasilias CD4 second	22 (2%)	11 (9%)	
Baseline CD4 count			
CD4 count <200 cells	255 (24%)	83 (68%)	
CD4 count >200 cells	686 (65%)	21 (17%)	
Missing CD4 count	108 (10%)	18 (15%)	
Baseline regimen	/		
Tenofovir//Lamivudine/Dolutegravir	946 (90%)	104 (85%)	
Tenofovir/Emtricitabine//Efavirenz	84 (8%)	10 (8%)	
Other	19 (2%)	0 (0%)	
Missing	0 (0%)	8 (7%)	

230

231 Retention and viral load suppression outcomes

At 6 months after ART initiation, 815 of the 1,049 participants (77%) were considered continuously in care, 92 (9%) had disengaged from care, and 142 (14%) had a cyclical pattern of engagement (Table 3). The proportion continuously in care included 45 individuals (4%) who had formally transferred to other facilities. Disengagement was comprised of immediate disengagers (no visits after initiation, 3%) and those who did not return after the first post-initiation visit (6%), along with a small number of deaths (0.5%). Cyclical engagement was common, as anticipated from previous research[3].

A third of participants (33%) did not have a VL test during the first 6 months on ART, due largely to early
 mortality, transfer, or disengagement from care. Cyclical engagers were also less likely than continuous

engagers to have a VL test despite returning to care after a treatment interruption and were less likely to

- achieve viral suppression.
- 244

# 245 Table 3: Retention and VL suppression outcomes stratified by pattern of engagement

Outcome	Outcome definition	N, %	VL test observed	VL <50 copies/mL	VL 50-1000 copies/mL	VL >1000 copies/mL
N		1,049 (100%)	705 (67%)	498 (47%)	149 (14%)	58 (6%)
Continuously	ln care	770 (73%)	601 (78%)	432 (72%)	130 (22%)	39 (6%)
in care	Transferred	45 (4%)	5 (11%)	2 (40%)	3 (60%)	0 (0%)
Disengaged	Died	4 (0.5%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	Immediately disengaged	30 (3%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	Disengaged from care during first 6 months after ART initiation	58 (5.5%)	1 (2%)	0 (0%)	1 (100%)	0 (0%)
Cyclical engagement	Treatment interruption followed by re-engagement in care by 6 months after ART initiation	142 (14%)	98 (69%)	64 (65%)	15 (15%)	19 (19%)

247 248

249 Predictors of retention outcomes

250

We found several potential predictors of retention at 6 months after initiation (Table 4). Women had a lower risk of disengagement during the first six months than their male counterparts (adjusted relative risk (ARR) 0.76; 95% CI 0.59-0.98). Those who reported experiencing food scarcity were more likely to not remain continuously in care compared to clients who reported consistent access to food (RR = 1.31; 95% CI 1.02-1.67). Clients who reported newly initiating ART had a higher risk (RR = 1.47; 95% CI 1.02-2.12) of not continuing in care than did those who had attended at least one post-initiation visit at the

- time of study enrolment. Though our estimates lacked precision, results also suggested that clients with
  CD4 counts <200 cells/mm3 at initiation were more likely to remain in care at 6 months than those with</li>
  higher CD4 counts at ART start. Young adults aged 18-24 years also appeared more likely to not be
  continuously in care at 6 months on ART compared to older clients. Disengagement was higher among
  clients on an Efavirenz-containing regimen than for those on Dolutegravir (RR = 1.79; 95% Cl 1.21-2.66).
  We did not observe important differences in retention by level of education, or relationship status or
  other self-reported preferences or experiences of HIV service delivery.
- 264

265	Table 4: Predictors of disengagement during the first six months on ART treatment
-----	---

Characteristic	Continuously in care	Not continuously	Crude RR (95% Cl)	Adjusted RR (95% Cl)*
		in care	,	,
Ν	815	234		
Individual characteristics				
Age				
≥25 years	683 (79%)	185 (21%)	Ref	Ref
18-24 years	132 (73%)	49 (27%)	1.27 (0.97 - 1.67)	1.24 (0.93 - 1.65)
Gender				
Male	224 (75%)	75 (25%)	Ref	Ref
Female	591 (79%)	159 (21%)	0.85 (0.67-1.07)	0.76 (0.59 - 0.98)
Educational level				
Secondary/tertiary	512 (78%)	142 (22%)	Ref	Ref
Primary or less	303 (77%)	92 (23%)	1.07 (0.85 - 1.35)	1.09 (0.87 – 1.38
Relationship status				
Have a partner	259 (78%)	75 (22%)	Ref	Ref
No partner/not living with a	556 (78%)	159 (22%)	0.99 (0.78 - 1.26)	1.00 (0.79 – 1.29
partner				
Food scarcity				
Never/seldom	639 (79%)	166 (21%)	Ref	Ref
Sometimes/often	176 (72%)	68 (28%)	1.35 (1.06 - 1.72)	1.31 (1.02 - 1.67)
Can obtain ZAR100 cash for health				
care when required				
Easy	360 (78%)	100 (22%)	Ref	Ref
Difficult	455 (77%)	134 (23%)	1.05 (0.83 - 1.32)	1.04 (0.83 - 1.31)
Urban/rural facility				
Urban	441 (78%)	127 (22%)	Ref	Ref
Rural	374 (78%)	107 (22%)	0.99 (0.79 - 1.25)	1.02 (0.81 - 1.29)
HIV care and experiences				
ART status at study enrolment				
On treatment < 6 months	482 (81%)	114 (19%)	Ref	Ref
Newly initiating	208 (70%)	88 (30%)	1.55 (1.22 – 1.98)	1.54 (1.20 -1.97)
Re-engaging	125 (80%)	32 (20%)	1.07 (0.75 – 1.51)	1.05 (0.74 - 1.49
WHO staging at initiation				
Stage1	703 (78%)	201 (22%)	Ref	Ref
Stage2	63 (77%)	19 (23%)	1.04 (0.69 - 1.57)	1.13 (0.75 - 1.73
Stage 3 or 4	32 (78%)	9 (22%)	0.99 (0.55 - 1.78)	1.07 (0.58 - 1.95

Characteristic	Continuously in care	Not continuously in care	Crude RR (95% Cl)	Adjusted RR (95% CI)*
Unknown	17 (77%)	5 (23%)	1.02 (0.47 - 2.23)	1.03 (0.48 - 2.24)
Baseline CD4 count	,	. ,		
≥200 copies	525 (77%)	161 (23%)	Ref	Ref
<200 copies	207 (81%)	48 (19%)	0.80 (0.60 1.07)	0.79 (0.58 – 1.07)
Missing	83 (77%)	25 (23%)	0.99 (0.68 - 1.43)	1.05 (0.72 – 1.54)
Baseline regimen	00 (7770)	23 (2370)	0.00 (0.00 1.10)	1.03 (0.72 1.34)
Tenofovir/Lamivudine/Dolutegravir	742 (78%)	204 (22%)	Ref	Ref
Tenofovir/Emtricitabine/Efavirenz	58 (69%)	26 (31%)	1.44 (1.02 - 2.02)	1.79 (1.21 - 2.66)
Other	15 (79%)	4 (21%)	0.98 (0.41 - 2.35)	1.18 (0.48 - 2.89)
Preferences	13 (7576)	4 (21/0)	0.50 (0.41 2.55)	1.10 (0.40 2.05)
Do you wish that this clinic offered you				
more/the same/less HIV information?				
Same or less	418 (78%)	121 (22%)	Ref	Ref
More	418 (78%) 397 (78%)		0.99 (0.79 - 1.24)	1.00 (0.80 - 1.25)
	397 (78%)	113 (22%)	0.99 (0.79 - 1.24)	1.00 (0.80 - 1.25)
Do you wish that this clinic offered you more/ the same/less counselling?				
Same or less	420 (78%)	116 (22%)	Ref	Ref
More	395 (77%)	118 (23%)	1.06 (0.85 - 1.33)	1.06 (0.85 - 1.32)
I prefer to attend clinic visits				
Alone	705 (78%)	195 (22%)	Ref	Ref
With someone	110 (74%)	39 (26%)	1.21 (0.90 - 1.63)	1.12 (0.82 - 1.51)
I prefer to receive HIV treatment				
outside the clinic				
Νο	289 (78%)	81 (22%)	Ref	Ref
Yes	526 (77%)	153 (23%)	1.03 (0.81 - 1.31)	1.05 (0.83 - 1.33)
Facility experience				
Some staff do not treat patients with				
sufficient respect				
Disagree	611 (78%)	171 (22%)	Ref	Ref
Agree	151 (76%)	49 (24%)	1.12 (0.85 - 1.48)	1.15 (0.87 - 1.51)
The queues to see a doctor or nurse				
are too long at this facility				
Disagree	211 (77%)	63 (23%)	Ref	Ref
Agree	538 (79%)	146 (21%)	0.93 (0.72 - 1.20)	0.94 (0.73 - 1.21)
In this clinic, you're able to talk to the	. /	V /	. /	,,
doctors or nurses in private				
Disagree	97 (76%)	30 (24%)	Ref	Ref
Agree	704 (78%)	197 (22%)	0.93 (0.66 - 1.30)	0.92 (0.66 - 1.29)
The health workers are too busy to			. ,	. ,
listen to my problems				
Disagree	728 (78%)	202 (22%)	Ref	Ref
Agree	72 (73%)	26 (27%)	1.22 (0.86 - 1.74)	1.25 (0.89 - 1.76)
The doctors and nurses discussed the	. /	· · · /		,,
treatment fully with me				
Disagree	43 (75%)	14 (25%)	Ref	Ref
Agree	767 (78%)	220 (22%)	0.91 (0.57 - 1.45)	0.90 (0.56 - 1.44)
I find it easy to tell the health workers		/		

when I have missed taking my tablets

Characteristic	Continuously in care	Not continuously	Crude RR (95% Cl)	Adjusted RR (95% Cl)*
		in care		
Disagree	146 (78%)	42 (22%)	Ref	Ref
Agree	573 (78%)	159 (22%)	0.97 (0.72 - 1.31)	0.95 (0.71 - 1.28)
The facilities are dirty				
Disagree	704 (78%)	195 (22%)	Ref	Ref
Agree	84 (74%)	30 (26%)	1.21 (0.87 -1.69)	1.26 (0.91 - 1.75)

267 \*Adjusted for age, gender, baseline CD4 count, and ART status at enrollment

269 *Qualitative findings* 

270

271 When FGD participants were asked qualitatively about barriers to adherence in the first six months,

several key insights emerged at each social ecological level, though the majority pertained to

interpersonal and health facility levels (Table 5). At the individual level, key barriers were primarily

274 financial, though they affected continuity of care through different mechanisms. Participants reported

the cost of travel to the facility as a barrier that directly hampered their ability to obtain care and collect

- 276 medication. They also described general food scarcity which limited their willingness and ability to take
- the medication for fear of side effects. Neither of these two financial barriers are surprising given that
- 278 over half of respondents in the analytic and FGD samples were unemployed at baseline and nearly a
- 279 quarter of respondents reported 'sometimes/often' experiencing food scarcity which was associated
- with an increased likelihood of disengagement in the first six months.
- 281

# Table 5. Qualitative barriers to adherence in the early treatment period, fit to the social ecological model

Level	Barrier	Quotations
Individual	Financial <b>cost</b> of travel	"I have trouble with transportation money. My date arrives and I don't have money for transport. I even go and borrow from a friend."
	Food scarcity	"The medication intake requires one to eat food, when you do not have income to buy food, it really becomes a problem. I am discouraged to collect my medication from the clinic, because I know that I will not take it since there is no food, So I might as well stay without the pills because of the lack of income"
Interpersona	Stigma deters people from disclosing their status to friends and loved ones;	"When I started taking treatment things changed at home. They had a discussion about me from day 1. I was given my own plate and spoon. I had my own things that I must use separately for everything I do in the house. So I am known as "that person on treatment" at home."
	feelings of ostracization within families	"Sometimes it happens that in a family you are the only one like this. What scares me is that I am the only one in the family with this problem. I can't open up and talk to a person that is HIV negative and tell them I am positive. It would have been easier if somebody else was dealing with the same problem in my family

<sup>268</sup> 

		"It is hard just to tell even friends what is going on and that you are on medication. Sometimes you end defaulting just to impress your family or the partner. You want to be seen as innocent to your partner."
Health facility	-	"Sometimes nurses come to the clinic with their own moods and attitudes and it becomes difficult to ask her about anything. It would be nice if you can walk in happy and leave happy. What happens sometimes is that you walk in well and leave feeling sick because the nurse who was attending to you has left you feeling stressed. You are even struggling to take instructions. "
		"But the problem started with the nurse who tested me When she finished testing me she was like "you are busy with boys here". She did not even know So next time when they say go to the social worker, no thank you, because already you have judged me. You have categorised me, even if I was running around with boys, there was no need for you to say that."
	Inefficient filing system consumes staff time; results in multiple files per client and long wait times	"The problem is the missing files at the clinics. They will come and ask when you last attended the clinic when it is clearly stated on the appointment card. I am not sure how files go missing, but they do. You sit for 30 minutes whilst they are still looking for your file. People behind you will pass you and go in. You end up being attended late. There really needs to be another strategy when it comes to the filing system."
		"My second and third visit were the same. My file was missing, I always have a new file and on subsequent visits the files will be all together and you just wonder where came from now. I had just to accept to have a lot of files."
	Clients perceive the lack of privacy they have at the clinic; fear of seeing someone you know	"What makes people to be anxious about going to the clinic is meeting people they know that work at the clinic. They worry about them spreading the information to other people they know. They feel like hiding so that they will not be seen by people that know them at the clinic. It would help if clinic staff took the issue of confidentiality seriously. That is the reason people do not like going to the clinic."
Community	Work and opportunity costs of care seeking	"My clinic date was on the 16th. My boss does not care if it is your clinic date. He wants you at work. So I wanted to leave work early but I couldn't. When I got of the taxi, it was already 16h00. I figured it was too late to go to the clinic. On the next day I woke up early to collect my treatment. When I got there I was number 2 but could not get assistance because there were prioritising people that came after me with appointment cards. I got angry and asked them what was happening and they said that I will be seen last because I missed the date."
		"Sometimes I will get the temporal job. I can't tell my boss that I have a temporal job. Even if I am given the day, when I come to the clinic at 8 o'clock, sometime I will get the treatment at past 2 or to 3. So, I would decide that it is better to go next week because I will stay without having something to eat and no money in my pocket and no nothing. Sometime I will prefer not to come because I have no

money, plus the time I am going to spend at the clinic"
At the interpersonal level, stigma and non-disclosure, two inextricably linked concepts, emerged as key
barriers. Participants reported experiencing changes in how they were treated within their own homes
and identified feelings of shame related to fear and gossip within their social networks. As illustrated in
the quotes presented below, these feelings of stigma and shame can result in behaviors related to
disengagement including non-disclosure or defaulting on treatment.
Most of the barriers that emerged were at the facility level, wherein respondents reported negative
interactions with health facility staff, inefficiencies in clinic processes, and a fear of disclosure because of
a lack of privacy as demotivating factors that contributed to disengagement in the early treatment
period. Respondents were frustrated with the processes of having to start a new file at every visit, which
extended their wait time both while the provider searched for the old file and then started a new file.
Respondents also explained that they experienced punitive repercussions for showing up a day or two
late, including being shouted at or demoted to the back of the queue. Others described situations in
which the felt they were being shamed or judged for having HIV.
Finally, at the community level, barriers pertained to challenges associated with missing work multiple
times for clinic appointments, as well as other opportunity costs associated with care-seeking.
Participants described challenges negotiating time off from work to get to the clinic. This was a
challenge both for those with permanent jobs and for those with temporary positions. Participants also
described holding jobs that required them to travel which prevented them from getting to the clinic.
Discussion
Reaching the second of UNAIDS's "three 95s" [19]initiating and retaining 95% of known PLWH on ART
has remained challenging for high HIV burden countries like South Africa. Addressing high rates of
disengagement from care after treatment initiation is likely the only effective pathway to achieving
current targets [20]. To do this, obstacles to establishing and remaining continuously in care during the
period with the highest risk for disengagement—patients' first six months on ART—must be identified

and solutions to overcome these challenges explored.

315

316 Results of the PREFER study reported here confirmed high rates of disengagement during the early 317 treatment period; overall nearly a quarter of participants were not continuously in care by 6 months 318 after ART initiation, similar to rates of disengagement reported in other studies in South Africa [21]. A 319 cyclical pattern of engagement characterized by an interruption in treatment of >28 days followed by re-320 engagement in care was more frequently observed during the early treatment period than was outright 321 disengagement from care. Cyclical engagers in our cohort were most likely to have unsuppressed viral 322 loads (>1000 copies/mL) at their six-month monitoring point, suggesting that they were indeed not 323 accessing medication during the interruptions. This is consistent with other findings from South African 324 cohorts suggesting poor treatment outcomes for returning engagers; one study found less than a third of 325 clients maintain a suppressed VL one year after re-engaging in care [22] while another reported a four-326 fold increase in mortality risk among those who interrupt care during the first 6 months on ART [23]. 327

Quantitative results of our study identified some key groups that may require prioritization for retention interventions during the early treatment period. Not surprisingly, men, youth (18-24 years), and those newly initiating ART were groups most at risk for not bring continuously on ART by 6 months after treatment initiation. The first two populations are well-described demographic categories at risk of disengagement [24,25], while estimates for the latter group are likely impacted by survival bias –those in the study who had already returned for at least one clinic visit at the time of study enrollment had already been retained in care longer than the "immediate disengagers."

335

336 We also found that those initiating a dolutegravir-based regimen at initiation were more likely to be 337 continuously in care at 6 months than were those on efavirenz-based regimens. Dolutegravir-based 338 regimens have been shown to be effective at rapidly suppressing virus and durable in terms of resistance 339 development; clients also report fewer side effects on dolutegravir than other drug classes available in 340 South Africa [26,27]. Also, not surprisingly, but less well documented in prior research, we found that 341 clients in our study who either self-reported prior use of ART or were re-engaging in care at study 342 enrolment were more likely to be receiving efavirenz-based ART. In this context, treatment regimen may 343 be a proxy for prior treatment experience, as previously disengaging from care may be independently 344 associated both with an efavirenz regimen and an increased risk for a subsequent treatment interruption 345 if the factors leading to the first episode of disengagement are not addressed.

346

347 While these findings are consistent with other work and begin to identify groups to prioritize, they offer 348 few practical solutions. Although they are considered the highest risk groups, an absolute majority of 349 men, young people, and previous disengagers do remain continuously in care (i.e. continuous retention 350 exceeds 50%) and do not require additional intervention to achieve viral suppression. There is a need to 351 get beyond these general characteristics if we are to identify important and modifiable drivers of 352 disengagement and find feasible solutions. PREFER made some progress in this direction. We found that 353 food scarcity and the use of an efavirenz-based regimen were both associated with a significant 354 reduction in continuous engagement. While our estimates lacked precision, we also observed that 355 participants with unfavorable views of their treatment experience--long waiting queues and negative 356 interactions with healthcare workers, such as clients who report re-engaging in care being attended to 357 after all other booked clients--were also less likely to remain continuously engaged. Finally, as expected, 358 we observed high immediate disengagement from care (no further visits after initiation), indicating that 359 for many clients, the initiation visit itself offers the only chance to influence later outcomes.

360

361 The qualitative findings offered further insights in this regard, while also reinforcing existing evidence 362 about the patient-provider relationship [28–30]. Despite two decades of societal experience with HIV 363 treatment since the rollout of ART in South Africa, study participants reported that stigma and social 364 ostracization remain major impediments to treatment continuity. Clients reported this barrier both in 365 their homes and at facilities, where negative language and shaming of clients living with HIV persists and 366 privacy may be compromised. Another key facility-level barrier to visit adherence that clients reported 367 was the inefficiencies created by poorly organized filing systems that result in loss of client information, 368 duplicate files, and excessive waiting times at each facility visit.

369

370 While societal stigma is not easily addressed, many of the facility-level barriers identified in our study are 371 modifiable within the healthcare system. A systematic review of interventions to improve retention [31] 372 found positive benefits of community-based service delivery and adherence clubs, bearing in mind that 373 the models reviewed were underpinned by supportive interventions that addressed psychosocial 374 barriers to adherence. Positive motivational counselling skills development [32] has been shown to 375 improve provider-client relationships and subsequent retention and viral suppression [33]. Though 376 primarily directed at lay counsellors, application of person-centered language and approaches across all 377 facility staff cadres could positively affect client experience and thus long term and continuous

engagement in care. Low-intensity models of care for established ART clients may reduce pressure onproviders and allow them to spend more time with initiating and new patients [34].

380

381 Our results also identified financial constraints as a barrier to continuity of HIV care and treatment. Both 382 the quantitative and qualitative results indicated that clients frequently found it difficult to obtain the 383 cash needed to access health care at the prescribed intervals. Transport costs were most often noted, 384 but other costs, such as child care, loss of income due to missing work for a day, and purchasing of food 385 and drinks while waiting in queues, also present difficulties for clients who must make frequent clinic 386 visits during the first 6 months on ART. While financial incentives have been shown to improve rates of 387 retention and viral suppression in the first 6 months on ART [35], it is unclear whether these incentives 388 result in sustained continuity of care and if an intervention like this could be sustainably scaled in a 389 national program as large as South Africa's.

390

391 Many of the barriers that impede engagement in the early treatment period could potentially be 392 addressed by existing service delivery options found within many countries' differentiated service 393 delivery programs. Early period patients may benefit from fast-tracking, multi-month dispensing, and 394 flexibility of location for medication pickups as much as, if not more than, established patients. 395 Recognizing this potential, South Africa's most recent update to its national guidelines [36] introduces an 396 initial viral load monitoring test at 3 months after initiation, rather than the usual six. This change 397 effectively brings forward eligibility for a differentiated model of service delivery forward to 4 months 398 after initiation, the first routine clinic visit at which viral load test results are available. For clients who 399 remain in care for the first four months, this is a promising improvement. As noted, however, most 400 disengagement during the early treatment period occurs within the first 3 months.

401

402 Our study had a number of limitations. First, the sample size was modest, in terms of both number of 403 study sites and number of participants, and generalizability to districts and provinces not included in the 404 survey will require caution. Second, study clients were enrolled at any point up to 6 months after ART 405 initiation, which may have created the possibility of recall bias for questions pertaining to their 406 experiences and perceptions at ART initiation. As mentioned above, this enrollment strategy also 407 potentially created a survival bias in our outcome results. We note, for example, that 86% of PREFER 408 study participants had WHO stage recorded as Stage 1. This may reflect the need for clients to be well 409 enough to participate in the study, resulting in exclusion of some of those with Stage 3 or 4 defining

410 conditions. While we cannot exclude this possibility, we note that nearly a quarter (24%) of those 411 enrolled presented with CD4 counts <200, the immunologic definition for advanced HIV disease, which is 412 consistent with other estimates of AHD populations [37]. Third, we used participant self-report to 413 determine prior ART use, which has previously been observed to be subject to much under-reporting; 414 estimates suggest that anywhere from 20-50% of clients presenting for initiation of ART have previously 415 used ART before [38]. To the extent to which this exposure misclassification occurred in the PREFER 416 sample, our results will under-estimate the effect of prior ART use on risk of disengagement from care. 417 Finally, we relied on routinely collected EMR data to ascertain participant ART retention outcomes at 6 418 months after ART initiation. This approach may also introduce bias due to outcome misclassification as 419 our data is limited to visits observed at the initiating facility--we did not observe participants accessing 420 care at other facilities. To the extent to which silent transfers such as these have occurred, our results 421 will over-estimate rates of disengagement.

422

#### 423 Conclusion

424

425 Despite these limitations, this study identified a number of potentially modifiable factors that, if 426 addressed, could improve early HIV treatment outcomes, in particular, improving clients' experiences at 427 healthcare facilities and offering less expensive access to care, in terms of both time and transport costs. 428 Accelerating eligibility for DSD models, so that even new ART clients can pick up medications at 429 convenient locations and receive larger quantities of medications at a time, offers one way to address 430 some of these issues. Strengthening the implementation of the 2023 revision to the National ART 431 Guidelines [16], particularly with regard to CD4 count and viral load monitoring, could assist in 432 identification and support of clients with advanced HIV disease and those eligible for earlier enrollment 433 in differentiated service delivery options. While we did not identify a silver bullet for targeting clients at 434 risk of disengagement, we began to describe subgroups who may benefit from more attention, such as 435 previous disengagers. We hope that future research will further explore the characteristics of those who 436 do, and do not, need intervention to achieve successful outcomes.

437

## 438 Conflict of interest statement

439

440 The authors have no conflicts of interest to declare. Drs. Manganye and Malala are employees of the

441 government agency that has supervisory authority over the study sites.

442	
443	Authors' contributions
444	
445	MM, NS, LS, and SR conceived of and designed the study. NM, AM, and MB analyzed the data. VN
446	supervised data collection. LM and MM contributed to interpretation of results. MM, NS, AM, and SR
447	drafted the manuscript. All authors have read and approved the final manuscript.
448	
449	Acknowledgements
450	
451	We would like to thank the clients and staff of the study sites for their cooperation in allowing us to
452	conduct this study and the South Africa National Department of Health (NDOH) for approving this
453	research.
454	
455	Data availability
456	
457	Data generated by the study will be made publicly available in the Open BU repository
458	(https://open.bu.edu/) after the PREFER study protocol has been closed (anticipated closure December
459	2025). Until then, data will remain under the supervision of the Boston University Medical Campus IRB
460	and the University of the Witwatersrand Human Research Ethics Committee (HREC). Requests can be
461	sent to the BUMC IRB at medirb@bu.edu. Data extracted from routine medical records are owned by the
462	study sites and the South African National Department of Health and cannot be made publicly available
463	by the authors.
464	
465	Funding
466	
467	Funding for the study was provided by the Bill & Melinda Gates Foundation through INV-031690 to
468	Boston University. The funder had no role in study design, data collection and analysis, decision to
469	publish, or preparation of the manuscript.
470	
471	Ethics
472	

- 473 The PREFER study was approved by the Boston University Institutional Review Board (South Africa H-
- 474 42726, May 20, 2022) and by the University of the Witwatersrand Human Research Ethics Committee
- 475 (South Africa M220440, August 23, 2022). The protocol for South Africa was approved by Provincial
- 476 Health Research Committees through the National Health Research Database for each study district
- 477 (August 1, 2022 for West Rand; September 1, 2022 for King Cetshwayo and August 28, 2022 for
- 478 Ehlanzeni). The study is registered with ClinicalTrials.gov (NCT05454839).
- 479

#### 480 References

- 481 1. Fox MP, Rosen S. A new cascade of HIV care for the era of "treat all." PLoS Med. 2017;14:
  482 e1002268. doi:10.1371/journal.pmed.1002268
- 483 2. Rosen S, Grimsrud A, Ehrenkranz P, Katz I. Models of service delivery for optimizing a
- 484 patient's first six months on antiretroviral therapy for HIV: an applied research agenda.
- 485 Gates Open Res. 2020;4: 116.
- 486 3. Maskew M, Benade M, Huber A, Pascoe S, Sande L, Malala L, et al. Patterns of
- 487 engagement in care during clients' first 12 months after HIV treatment initiation in South
- 488 Africa: A retrospective cohort analysis using routinely collected data. PLOS Global Public
- 489 Health. 2024;4: e0002956. doi:10.1371/journal.pgph.0002956
- 490 4. Lilian RR, Rees K, Mabitsi M, McIntyre JA, Struthers HE, Peters RPH. Baseline CD4 and
- 491 mortality trends in the South African human immunodeficiency virus programme:
- 492 Analysis of routine data. South Afr J HIV Med. 2019;20: 1–10.
- 493 doi:10.4102/sajhivmed.v20i1.963
- 494 5. Zaniewski E, Dao Ostinelli CH, Chammartin F, Maxwell N, Davies MA, Euvrard J, et al.
- 495 Trends in CD4 and viral load testing 2005 to 2018: multi-cohort study of people living
- 496 with HIV in Southern Africa. J Int AIDS Soc. 2020;23: 1–10. doi:10.1002/jia2.25546
- 497 6. World Health Organization. Guidelines for Managing Advanced HIV Disease and Rapid
- 498 Initiation of Antiretroviral Therapy. 2017. Available:
- 499 https://www.who.int/publications/i/item/9789241550062
- 500 7. Benade M, Maskew M, Juntunen A, Flynn DB, Rosen S. Prior exposure to antiretroviral
- 501 therapy among adult patients presenting for HIV treatment initiation or reinitiation in
- 502 sub-Saharan Africa: a systematic review. BMJ Open. 2023;13: e071283.
- 503 doi:10.1136/bmjopen-2022-071283
- 504 8. Mavhandu-Ramarumo LG, Tambe LAM, Matume ND, Katerere D, Bessong PO.
- 505 Undisclosed exposure to antiretrovirals prior to treatment initiation: An exploratory
- 506 analysis. South Afr J HIV Med. 2021;22: 1–10. doi:10.4102/sajhivmed.v22i1.1200

507 9. IeDEA and COHERE Cohort Collaborations. Global Trends in CD4 Cell Count at the Start of

- 508 Antiretroviral Therapy: Collaborative Study of Treatment Programs. Clinical Infectious 509 Diseases. 2018 [cited 6 Feb 2018]. doi:10.1093/cid/cix915
- 510 10. Ford N, Migone C, Calmy A, Kerschberger B, Kanters S, Nsanzimana S, et al. Benefits and 511 risks of rapid initiation of antiretroviral therapy. Aids. 2017;0: 1.
- 512 doi:10.1097/QAD.00000000001671
- 515 12. Rosen S, Grimsrud A, Ehrenkranz P, Katz I. Models of service delivery for optimizing a

patient's first six months on antiretroviral therapy for HIV: An applied research agenda.
Gates Open Res. 2020;4: 1–15. doi:10.12688/gatesopenres.13159.1

- 518 13. Maskew M, Ntjikelane V, Juntunen A, Scott N, Benade M, Sande L, et al. Preferences for
- 519 services in a patient's first six months on antiretroviral therapy for HIV in South Africa and
- 520 Zambia (PREFER): research protocol for a prospective observational cohort study. Gates

521 Open Res. 2023;7: 119. doi:10.12688/gatesopenres.14682.1

522 14. National Department of Health. 2019 ART Clinical Guidelines. Pretoria; 2019.

- 523 15. National Department of Health. Adherence guidelines for HIV, TB and NCDS, updated
- 524 March 2020. Standard operating procedures: minimum package of interventions to 525 support linkage to care, adherence and retention. 2020.
- 526 16. National Department of Health. Minimum package of interventions to support linkage to
  527 care, adherence and retention in care standard operating procedures. 2023.
- 528 17. Kilanowski JF. Breadth of the Socio-Ecological Model. Journal of Agromedicine. Taylor and
  529 Francis Ltd.; 2017. pp. 295–297. doi:10.1080/1059924X.2017.1358971
- 530 18. Wanjala SW, Nyongesa MK, Luchters S, Abubakar A. Psychosocial and mental health
- 531 challenges facing perinatally HIV-infected adolescents along the Kenyan coast: a
- 532 qualitative inquiry using the socioecological model. Front Public Health. 2024;12:
- 533 1379262. doi:10.3389/fpubh.2024.1379262
- 534 19. Joint United Nations Programme on HIV/AIDS (UNAIDS). Understanding measures of
- 535 progress towards the 95–95–95 HIV testing, treatment and viral suppression targets.

536 2023; 1–2. Available: https://www.unaids.org/en/resources/documents/2024/progress537 towards-95-95

- 538 20. Meyer-Rath G, Jamieson L, Johnson LF. When the only intervention left to optimise is
- retention: Comparing the 2021 and 2016 South African HIV Investment Cases.
- 540 21. Benade M, Maskew M, Chilembo P, Mwanza WM, Sande L, Rosen S. Patterns of
- 541 engagement in care during clients' first 12 months after HIV treatment initiation in South
- 542 Africa: A retrospective cohort analysis using routinely collected data. AIDS 2024. Munich,
  543 Germany; 2024.
- 544 22. Keene CM, Euvrard J, Cassidy T, English M, Mcknight J, Orrell C, et al. Persistent
- 545 Challenges with Viral Suppression a Year After Return to Care: Evidence from South546 Africa.
- 547 23. Moolla H, Davies MA, Davies C, Euvrard J, Prozesky HW, Fox MP, et al. The effect of care
  548 interruptions on mortality in adults resuming antiretroviral therapy. AIDS. 2024;38: 1198–
  549 1205. doi:10.1097/QAD.00000000003859
- 550 24. Makurumidze R, Decroo T, Jacobs BKM, Rusakaniko S, Van Damme W, Lynen L, et al.
- 551 Attrition one year after starting antiretroviral therapy before and after the programmatic
- 552 implementation of HIV "Treat All" in Sub-Saharan Africa: a systematic review and meta-

553 analysis. BMC Infect Dis. 2023;23: 558. doi:10.1186/s12879-023-08551-y

- 554 25. Frijters EM, Hermans LE, Wensing AMJ, Devillé WLJM, Tempelman HA, De Wit JBF. Risk
- factors for loss to follow-up from antiretroviral therapy programmes in low-income and
  middle-income countries. AIDS. 2020;34: 1261–1288.
- 557 doi:10.1097/QAD.00000000002523
- 558 26. Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Mbombi MO, et al.
- 559 Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. N Engl J Med.
- 560 2019;381: 803–815. doi:10.1056/NEJMoa1902824
- 561 27. NAMSAL ANRS 12313 Study Group; Kouanfack C, Mpoudi-Etame M, Omgba Bassega P,
- 562 Eymard-Duvernay S, Leroy S, Boyer S, Peeters M, Calmy A DE. Dolutegravir-Based or Low-
- 563 Dose Efavirenz– Based Regimen for the Treatment of HIV-1. N Engl J Med. 2019;381: 816–
- 564 826. doi:10.1056/NEJMoa1904340

565 28. George S, McGrath N. Social support, disclosure and stigma and the association with non-

- adherence in the six months after antiretroviral therapy initiation among a cohort of HIV-
- 567 positive adults in rural KwaZulu-Natal, South Africa. AIDS Care. 2019;31: 875–884.

568 doi:10.1080/09540121.2018.1549720

- 569 29. Killian C, West RL, Orrell C, Gifford A, Haberer JE, Halim N, et al. Negative clinic
- 570 experiences as a barrier to care for people with HIV and their impact on patient
- 571 preferences for intervention support: a qualitative study in Cape Town, South Africa. AIDS
- 572 Care. 2024;36: 1222–1231. doi:10.1080/09540121.2024.2346255
- 573 30. Zanolini A, Sikombe K, Sikazwe I, Eshun-Wilson I, Somwe P, Bolton Moore C, et al.
- 574 Understanding preferences for HIV care and treatment in Zambia: Evidence from a
- 575 discrete choice experiment among patients who have been lost to follow-up. Tsai AC,
- 576 editor. PLoS Med. 2018;15: e1002636. doi:10.1371/journal.pmed.1002636
- 577 31. Penn AW, Azman H, Horvath H, Taylor KD, Hickey MD, Rajan J, et al. Supportive
- 578 interventions to improve retention on ART in people with HIV in low- and middle-income 579 countries: A systematic review. PLoS One. 2018;13. doi:10.1371/JOURNAL.PONE.0208814
- 580 32. Mokhele I, Sineke T, Vujovic M, Ruiter RAC, Miot J, Onoya D. Improving patient-centred
- 581 counselling skills among lay healthcare workers in South Africa using the Thusa-Thuso
- 582 motivational interviewing training and support program. PLOS Global Public Health.
- 583 2024;4: 1–17. doi:10.1371/journal.pgph.0002611
- 33. Onoya D, Sineke T, Mokhele I, Vujovic M, Holland K, Ruiter RAC. Improving Retention and
  HIV Viral Suppression: A Cluster Randomised Pilot Trial of a Lay Counsellor Motivational
  Interviewing Training in South Africa. medRxiv. 2024; 1–30.
- 587 doi:10.1101/2024.09.20.24314048
- 588 34. CCMDD in South Africa: provider workload, responsibilities, and time use. Johannesburg;
  589 2023 Jun.
- 590 35. Fahey CA, Njau PF, Katabaro E, Mfaume RS, Ulenga N, Mwenda N, et al. Financial
- 591 incentives to promote retention in care and viral suppression in adults with HIV initiating
- 592 antiretroviral therapy in Tanzania: a three-arm randomised controlled trial. Lancet HIV.
- 593 2020;7: e762-e771. doi:10.1016/S2352-3018(20)30230-7

- 594 36. South African National Department of Health. 2023 ART Clinical Guidelines for the
- 595 Management of HIV in Adults, Pregnancy and Breastfeeding, Adolescents, Children,
- 596 Infants and Neonates. 2023. Available:
- 597 //www.knowledgehub.org.za/system/files/elibdownloads/2020-05/2019 ART Guideline
  598 28042020 pdf.pdf
- 599 37. de Waal R, Wools-Kaloustian K, Brazier E, Althoff KN, Jaquet A, Duda SN, et al. Global
- 600 trends in CD4 count measurement and distribution at first antiretroviral treatment
- 601 initiation. Clin Infect Dis. 2024. doi:10.1093/cid/ciae548
- 602 38. Benade M, Maskew M, Juntunen A, Flynn DB, Rosen S. Prior exposure to antiretroviral
- 603 therapy among adult patients presenting for HIV treatment initiation or reinitiation in
- 604 sub-Saharan Africa: A systematic review. BMJ Open. 2023;13: 1–11.
- 605 doi:10.1136/bmjopen-2022-071283